Stage IV NSCLC: pre-diagnosis statin use linked to improved survival
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Statin drugs appear to have an anticancer effect in advanced lung cancer; this has already been observed in other cancer types.
Retrospective database study using the Surveillance, Epidemiology and End Results registry linked to Medicare claims to identify 5118 patients 65 y of age diagnosed with stage IV non-small cell lung cancer (NSCLC) between 2007 and 2009.
Survival of patients receiving vs not receiving statins before diagnosis was compared.
27% of patients received statins at time of lung cancer diagnosis.
Median survival for the statin group was 7 vs 4 mo for nonstatin users (P<.001).
Propensity score analyses showed statin use was associated superior OS (HR, 0.76; 95% CI, 0.73-0.79) and lung c...